Mitotane: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 47: Line 47:
}}
}}


'''Mitotane''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]], [[Japanese Accepted Name|JAN]]) (brand name '''Lysodren'''), also known as '''1,1-(dichlorodiphenyl)-2,2-dichloroethane''' ('''o,p'-DDD'''), is a [[steroidogenesis inhibitor]] which is used as an [[antineoplastic]] medication used in the treatment of [[adrenocortical carcinoma]].<ref name="JamesonGroot2010">{{cite book|author1=J. Larry Jameson|author2=Leslie J. De Groot|title=Endocrinology - E-Book: Adult and Pediatric|url=https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA1888|date=18 May 2010|publisher=Elsevier Health Sciences|isbn=1-4557-1126-8|pages=1888–}}</ref><ref name="pmid15898346">{{cite journal |vauthors=Hahner S, Fassnacht M |title=Mitotane for adrenocortical carcinoma treatment |journal=Current opinion in investigational drugs (London, England : 2000) |volume=6 |issue=4 |pages=386–94 |date=April 2005 |pmid=15898346 |doi= |url=}}</ref> It is a [[chemical derivative|derivative]] of {{abbrlink|DDT|dichlorodiphenyltrichloroethane}} and an [[isomer]] of {{abbrlink|DDD|dichlorodiphenyldichloroethane}}.<ref name="PubChem">[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4211 Information from PubChem]</ref> Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease.
'''Mitotane''', sold under the brand name '''Lysodren''', is a [[steroidogenesis inhibitor]] which is used as an [[antineoplastic]] medication used in the treatment of [[adrenocortical carcinoma]].<ref name="JamesonGroot2010">{{cite book|author1=J. Larry Jameson|author2=Leslie J. De Groot|title=Endocrinology - E-Book: Adult and Pediatric|url=https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA1888|date=18 May 2010|publisher=Elsevier Health Sciences|isbn=1-4557-1126-8|pages=1888–}}</ref><ref name="pmid15898346">{{cite journal |vauthors=Hahner S, Fassnacht M |title=Mitotane for adrenocortical carcinoma treatment |journal=Current opinion in investigational drugs (London, England : 2000) |volume=6 |issue=4 |pages=386–94 |date=April 2005 |pmid=15898346 |doi= |url=}}</ref> It is a [[chemical derivative|derivative]] of {{abbrlink|p,p'-DDT|dichlorodiphenyltrichloroethane}} and an [[isomer]] of {{abbrlink|p,p'-DDD|dichlorodiphenyldichloroethane}}, and is also known as '''1,1-(dichlorodiphenyl)-2,2-dichloroethane''' ('''o,p'-DDD''').<ref name="PubChem">[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4211 Information from PubChem]</ref>


==Medical uses==
Mitotane has been produced by [[Bristol Myers Squibb]] SpA but it is marketed as an [[orphan drug]] due to the small number of patients in need of it. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone.<ref>{{cite journal|journal=N Engl J Med. | year = 2007 | volume = 356 | issue = 23 | pages = 2372–2380 | title=Adjuvant mitotane treatment for adrenocortical carcinoma|vauthors=Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A|doi=10.1056/NEJMoa063360|pmid=17554118}}</ref>
Mitotane has been produced by [[Bristol Myers Squibb]] SpA but it is marketed as an [[orphan drug]] for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone.<ref>{{cite journal|journal=N Engl J Med. | year = 2007 | volume = 356 | issue = 23 | pages = 2372–2380 | title=Adjuvant mitotane treatment for adrenocortical carcinoma|vauthors=Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A|doi=10.1056/NEJMoa063360|pmid=17554118}}</ref>


==Side effects==
⚫
Mitotane alters steroid peripheral metabolism, directly suppresses the adrenal cortex, and alters cortisone metabolism, leading to [[hypocortisolism]]. It specifically acts, most importantly, as an [[enzyme inhibitor|inhibitor]] of [[cholesterol side-chain cleavage enzyme]] (P450scc, CYP11A1), and also acts an inhibitor of [[11β-hydroxylase]] (CYP11B1), [[18-hydroxylase]] (aldosterone synthase, CYP11B2), and [[3β-hydroxysteroid dehydrogenase]] (3β-HSD) to a lesser extent.<ref name="JamesonGroot2010" /><ref name="HarrisBouloux2014">{{cite book|author1=Philip E. Harris|author2=Pierre-Marc G. Bouloux|title=Endocrinology in Clinical Practice, Second Edition|url=https://books.google.com/books?id=tZE-AwAAQBAJ&pg=PA216|date=24 March 2014|publisher=CRC Press|isbn=978-1-84184-951-5|pages=216–}}</ref>
⚫
The use of mitotane is unfortunately limited by [[side effect]]s,<ref name="HarrisBouloux2014" /> which, as reported by Schteinberg et al., include [[anorexia (symptom)|anorexia]] and [[nausea]] (88%), [[diarrhea]] (38%), [[vomiting]] (23%), decreased [[memory]] and ability to concentrate (50%), [[rash]] (23%), [[gynecomastia]] (50%), [[arthralgia]] (19%), and [[leukopenia]] (7%).<ref>{{cite journal|vauthors=Schteinberg DE, Motazedi A, NoonanRA, Thompson NW|title=Treatment of Adrenal Carcinomas|journal=Arch.Surg. | year = 1982 | volume = 117 | pages = 1142–1149}}</ref>


==Pharmacology==
⚫
The use of mitotane is unfortunately limited by side effects,<ref name="HarrisBouloux2014" /> which, as reported by Schteinberg et al., include [[anorexia (symptom)|anorexia]] and [[nausea]] (88%), [[diarrhea]] (38%), [[vomiting]] (23%), decreased [[memory]] and ability to concentrate (50%), [[rash]] (23%), [[gynecomastia]] (50%), [[arthralgia]] (19%), and [[leukopenia]] (7%).<ref>{{cite journal|vauthors=Schteinberg DE, Motazedi A, NoonanRA, Thompson NW|title=Treatment of Adrenal Carcinomas|journal=Arch.Surg. | year = 1982 | volume = 117 | pages = 1142–1149}}</ref>
⚫
Mitotane is an inhibitor of the [[adrenal cortex]]. It acts as an [[enzyme inhibitor|inhibitor]] of [[cholesterol side-chain cleavage enzyme]] (P450scc, CYP11A1), and also of [[11β-hydroxylase]] (CYP11B1), [[18-hydroxylase]] (aldosterone synthase, CYP11B2), and [[3β-hydroxysteroid dehydrogenase]] (3β-HSD) to a lesser extent.<ref name="JamesonGroot2010" /><ref name="HarrisBouloux2014">{{cite book|author1=Philip E. Harris|author2=Pierre-Marc G. Bouloux|title=Endocrinology in Clinical Practice, Second Edition|url=https://books.google.com/books?id=tZE-AwAAQBAJ&pg=PA216|date=24 March 2014|publisher=CRC Press|isbn=978-1-84184-951-5|pages=216–}}</ref> In addition, mitotane has direct and selective [[cytotoxic]] effects on the adrenal cortex, via an unknown mechanism, and thereby induces permanent adrenal cortex atrophy similarly to DDD.<ref name="MPHMD2011">{{cite book|author1=Eudocia Quant Lee, MD, MPH|author2=David Schiff, MD|author3=Patrick Y. Wen, MD|title=Neurologic Complications of Cancer Therapy|url=https://books.google.com/books?id=52qyu5XPqM4C&pg=PA179|date=28 September 2011|publisher=Demos Medical Publishing|isbn=978-1-61705-019-0|pages=179–}}</ref><ref name="Kannan2012">{{cite book|author=C.R. Kannan|title=The Adrenal Gland|url=https://books.google.com/books?id=WqXSBwAAQBAJ&pg=PA160|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4613-1001-3|pages=160–}}</ref>

==Society and culture==
''Mitotane'' is the [[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]], and [[Japanese Accepted Name|JAN]] of mitotane.


==Veterinary use==
==Veterinary use==

Revision as of 07:04, 8 June 2017

Mitotane
Clinical data
Trade namesLysodren
Other names1,1-(Dichlorodiphenyl)-2,2-dichloroethane; o,p'-DDD
AHFS/Drugs.comMonograph
MedlinePlusa608050
License data
Pregnancy
category
  • C
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: WARNING[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability40%
Protein binding6%
Elimination half-life18 to 159 days
Identifiers
  • (RS)-1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.152 Edit this at Wikidata
Chemical and physical data
FormulaC14H10Cl4
Molar mass320.04 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • Clc1ccccc1C(c2ccc(Cl)cc2)C(Cl)Cl
  • InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H checkY
  • Key:JWBOIMRXGHLCPP-UHFFFAOYSA-N checkY
  (verify)

Mitotane, sold under the brand name Lysodren, is a steroidogenesis inhibitor which is used as an antineoplastic medication used in the treatment of adrenocortical carcinoma.[2][3] It is a derivative of p,p'-DDTTooltip dichlorodiphenyltrichloroethane and an isomer of p,p'-DDDTooltip dichlorodiphenyldichloroethane, and is also known as 1,1-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).[4]

Medical uses

Mitotane has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone.[5]

Side effects

The use of mitotane is unfortunately limited by side effects,[6] which, as reported by Schteinberg et al., include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).[7]

Pharmacology

Mitotane is an inhibitor of the adrenal cortex. It acts as an inhibitor of cholesterol side-chain cleavage enzyme (P450scc, CYP11A1), and also of 11β-hydroxylase (CYP11B1), 18-hydroxylase (aldosterone synthase, CYP11B2), and 3β-hydroxysteroid dehydrogenase (3β-HSD) to a lesser extent.[2][6] In addition, mitotane has direct and selective cytotoxic effects on the adrenal cortex, via an unknown mechanism, and thereby induces permanent adrenal cortex atrophy similarly to DDD.[8][9]

Society and culture

Mitotane is the INN, USAN, BAN, and JAN of mitotane.

Veterinary use

Mitotane is also used to treat Cushing's disease (pituitary-dependent Cushing's syndrome) in dogs. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.[10]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ a b J. Larry Jameson; Leslie J. De Groot (18 May 2010). Endocrinology - E-Book: Adult and Pediatric. Elsevier Health Sciences. pp. 1888–. ISBN 1-4557-1126-8.
  3. ^ Hahner S, Fassnacht M (April 2005). "Mitotane for adrenocortical carcinoma treatment". Current opinion in investigational drugs (London, England : 2000). 6 (4): 386–94. PMID 15898346.
  4. ^ Information from PubChem
  5. ^ Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A (2007). "Adjuvant mitotane treatment for adrenocortical carcinoma". N Engl J Med. 356 (23): 2372–2380. doi:10.1056/NEJMoa063360. PMID 17554118.
  6. ^ a b Philip E. Harris; Pierre-Marc G. Bouloux (24 March 2014). Endocrinology in Clinical Practice, Second Edition. CRC Press. pp. 216–. ISBN 978-1-84184-951-5.
  7. ^ Schteinberg DE, Motazedi A, NoonanRA, Thompson NW (1982). "Treatment of Adrenal Carcinomas". Arch.Surg. 117: 1142–1149.
  8. ^ Eudocia Quant Lee, MD, MPH; David Schiff, MD; Patrick Y. Wen, MD (28 September 2011). Neurologic Complications of Cancer Therapy. Demos Medical Publishing. pp. 179–. ISBN 978-1-61705-019-0.{{cite book}}: CS1 maint: multiple names: authors list (link)
  9. ^ C.R. Kannan (6 December 2012). The Adrenal Gland. Springer Science & Business Media. pp. 160–. ISBN 978-1-4613-1001-3.
  10. ^ Canine Cushing’s Syndrome: Diagnosis and Treatment

External links


Retrieved from "https://en.wikipedia.org/w/index.php?title=Mitotane&oldid=784421847"